Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
about
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusInsulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitusInsulin degludec as an ultralong-acting basal insulin once a day: a systematic reviewEfficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysisThe Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential ImpactsMechanisms of hypoglycemia unawareness and implications in diabetic patientsCardiovascular effects of basal insulinsModern basal insulin analogs: An incomplete storySafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisSurvey of glargine use in 115 pregnant women with Type 1 diabetes.The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes.Insulin glargine safety in pregnancy: a transplacental transfer study.Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetesComparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesCurrent therapeutic options in type 2 diabetes mellitus: a practical approachClinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Analysis of insulin doses of Chinese type 2 diabetic patients with intensive insulin treatment.Glargine safety, diabetes and cancer.Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Identification of a small molecular insulin receptor agonist with potent antidiabetes activity.Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.Insulin glargine: the first clinically useful extended-action insulin analogue.Treat-to-target trials: uses, interpretation and review of concepts.Insulin glargine: a new basal insulin.Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients.Diabetes: glycaemic control in type 2 (drug treatments).The underuse of insulin therapy in North America.An overview of insulin glargine.Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.Insulin analogues and other developments in insulin therapy for diabetes.Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response.Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes.New insulin analogues and their impact on diabetes care.Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study.
P2860
Q24245192-F699ADAC-5B1D-420B-9C81-61228F41DD55Q24246084-4602CB09-C2F1-41CA-A46C-18B215580A4BQ24630395-56064A5A-A212-4BC7-8DA2-5CDEFD010078Q24656013-0ADA9042-0BFB-4E3A-A45D-5E2237985DA2Q26764842-65D9978F-DEC1-4D58-A589-0D5ECCAE8CDAQ26799608-8F3F8427-37F0-4F89-99A6-6CFD4D324CC2Q26800249-1F217248-7AB2-4F64-A1B1-859A50ACF5F7Q27015047-A5D8AE57-2066-4C5D-9425-FA599575D4CFQ28078467-5D8CFEBE-4C2B-40C4-95AB-0998395D2372Q33316172-03FAEE4B-C219-48B6-8427-7D03D0139035Q33442343-71B6B166-73F3-4E7E-B63C-DF41EC2E0C27Q33464541-4E49A03E-29C7-4C4E-A413-1E212D2C3510Q33556840-0362F03C-B90D-4B59-9BC7-600F3367619CQ33558371-7F3DF89E-FD90-419C-A6AE-62767A45D953Q33585766-AD36BA82-DB68-4307-A060-E642021A652EQ33723387-81212397-ADB9-4ED7-B609-2BF4326BEA5EQ33732607-A4540F26-3A4D-4E81-8757-ACC424F04B74Q33863413-7EC45A33-0F7B-4944-95B5-1A2D969F46A4Q33871459-7A458880-0C2F-447E-B125-A291EF45A8BBQ34312012-E35A9966-31B4-40EA-914F-15C5433EB835Q34326924-1C9CA6CD-CC06-474B-A6DC-1227A96F17EAQ34368524-D60A2C6B-3B20-45A7-A725-B6E5A18FF941Q34411271-F7D9C9D2-83C3-42E0-8322-4964C9DBFB76Q34449820-68D0006D-CAAE-4E13-9AF6-AF038A946781Q34515529-1BE80628-DF96-4B89-9AE7-136BBD86F668Q34540987-BE78C92B-25D2-4C31-BB58-6295FB0B9DCBQ34648626-51388A93-6316-471F-A6C4-83F6DD46AAD8Q34663438-8273B404-F89C-4BF0-BF10-3BD614815407Q34829290-75604B96-8AE7-4D16-BC21-3AD7B3E8F51FQ34906374-135DBD66-CE38-4409-AFAC-79EC7437E6F5Q34906412-E163F8BB-4582-4100-B732-46A552E58B31Q34906478-5AB0E467-69BE-44AB-ABE2-666D039379A4Q35044151-71BB607B-BEE5-4F8D-97CB-B2BC29D0D5E8Q35073384-BE1F9988-5A86-4455-8828-34A180543627Q35164710-9C7C8670-0398-4448-99B3-438CB18117A0Q35168159-5989A4EB-04AD-4DAC-9089-774F56F59CE0Q35175088-B4C7D144-C0D4-4043-BB8B-7F962CB0088FQ35611319-54A0E007-2867-45B7-B834-6618004C7DE0Q35694576-39151F68-9DF9-490E-8D9B-F21C79A7C4D6Q35772567-F9756BB8-B636-49B1-9B40-FF11E1D7A5AF
P2860
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@en
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@nl
type
label
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@en
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@nl
prefLabel
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@en
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@nl
P2093
P921
P1433
P1476
Less nocturnal hypoglycemia an ...... tes. HOE 901/3002 Study Group.
@en
P2093
A Dressler
HOE 901/300s Study Group
P304
P356
10.2337/DIACARE.23.8.1130
P407
P577
2000-08-01T00:00:00Z